A guideline for the outpatient management of glycaemic control in people with cancer
Open accessAbstract
Individuals with cancer are at increased risk of developing new‐onset diabetes mellitus and hyperglycaemia, and an estimated 20% of people with cancer already have an underlying diagnosis of diabetes mellitus. People with both cancer and diabetes may have an increased risk of toxicities, hospital admissions and morbidity, with hyperglycaemia potentially attenuating the efficacy of chemotherapy often secondary to dose reductions and early cessation. Numerous studies have demonstrated that hyperglycaemia is prognostic of worse overall survival and risk of cancer recurrence. These guidelines aim to provide the oncology/haemato‐oncology and diabetes multidisciplinary teams with the tools to manage people with diabetes commencing anti‐cancer/glucocorticoid therapy, as well as identifying individuals without a known diagnosis of diabetes who are at risk of developing hyperglycaemia and new‐onset diabetes.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Only a handful of guidelines, including Diabetes Canada and the Joint British Diabetes Societies, attempt to address specific subgroups such as pregnant individuals or oncology patients.
“only a handful of guidelines, including Diabetes Canada 26 and Joint British Diabetes Societies, 25 , 69 attempt to address specific subgroups, such as pregnant individuals or oncology patients.”
From A systematic review of glucocorticoid use in type 1 diabetes: Glycaemic effects and clinical management strategies (2026) · cites this paper as [69]
Cites
Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx225 · Cited by 2,367 · see citing works
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366 · see citing works
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
Stone, R. M., Mandrekar, S. J., Sanford, B. L., Laumann, K., Geyer, S., Bloomfield, C. D., Thiede, C., Prior, T. W., Döhner, K., Marcucci, G., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614359 · Cited by 2,250 · see citing works
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
Perl, A. E., Martinelli, G., Cortes, J. E., Neubauer, A., Berman, E., Paolini, S., Montesinos, P., Baer, M. R., Larson, R. A., Ustun, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1902688 · Cited by 1,287 · see citing works
Diabetes and Cancer: A Consensus Report
Giovannucci, E. L., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20078 · Cited by 1,065 · see citing works
Barone, B. B. (2008) · JAMA · doi:10.1001/jama.2008.824 · Cited by 881 · see citing works
Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies
Tsilidis, K. K., Kasimis, J. C., López, D. S., Ntzani, E., & Ioannidis, J. P. A. (2015) · BMJ · doi:10.1136/bmj.g7607 · Cited by 861 · see citing works
Paz-Ares, L., de Marinis, F., Dediu, M., Thomas, M., Pujol, J.-L., Bidoli, P., Molinier, O., Sahoo, T. P., Laack, E., Reck, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70063-3 · Cited by 610 · see citing works
Collateral damage: Insulin-dependent diabetes induced with checkpoint inhibitors
Stamatouli, A. M., Quandt, Z., Perdigoto, A. L., Clark, P. L., Kluger, H., Weiss, S. A., Gettinger, S., Sznol, M., Young, A., Rushakoff, R., et al. (2018) · Diabetes · doi:10.2337/dbi18-0002 · Cited by 590 · see citing works
Armstrong, A. J., Halabi, S., Eisen, T. G., Broderick, S., Stadler, W. M., Jones, R. J., Garcia, J. A., Vaishampayan, U. N., Picus, J., Hawkins, R. E., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00515-x · Cited by 427 · see citing works
Tamez-Pérez, H. E. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i8.1073 · Cited by 387 · see citing works
Pearson-Stuttard, J., Bennett, J., Cheng, Y. J., Vamos, E. P., Cross, A. J., Ezzati, M., & Gregg, E. W. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30431-9 · Cited by 335 · see citing works
Schlenk, R. F., Weber, D., Fiedler, W., Salih, H. R., Wulf, G. G., Salwender, H. J., Schroeder, T. A., Kindler, T., Lübbert, M., Wolf, D. G. F., et al. (2018) · Blood · doi:10.1182/blood-2018-08-869453 · Cited by 291 · see citing works
Programmed Cell Death-1 Inhibitor–Induced Type 1 Diabetes Mellitus
Clotman, K., Janssens, K., Specenier, P. M., Weets, I., & Block, C. E. M. D. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00728 · Cited by 235 · see citing works
Immune checkpoint inhibitors: An emerging cause of insulin-dependent diabetes
Kotwal, A., Haddox, C., Block, M., & Kudva, Y. C. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2018-000591 · Cited by 228 · see citing works
Immune checkpoint inhibitor‐induced Type 1 diabetes: a systematic review and meta‐analysis
Aktürk, H. K., Kahramangil, D., Sarwal, A., Hoffecker, L., Murad, M. H., & Michels, A. W. (2019) · Diabetic Medicine · doi:10.1111/dme.14050 · Cited by 193 · see citing works
Postoperative Mortality in Cancer Patients With Preexisting Diabetes
Barone, B. B., Yeh, H., Snyder, C. F., Peairs, K. S., Stein, K. B., Derr, R. L., Wolff, A. C., & Brancati, F. L. (2010) · Diabetes Care · doi:10.2337/dc09-1721 · Cited by 183 · see citing works
Roberts, A., James, J., Dhatariya, K., & Care, T. J. B. D. S. (. F. I. (2018) · Diabetic Medicine · doi:10.1111/dme.13675 · Cited by 158 · see citing works
Self-citationAgostino, N. M., Chinchilli, V. M., Lynch, C. J., Koszyk-Szewczyk, A., Gingrich, R., Sivik, J. M., & Drabick, J. J. (2010) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155210378913 · Cited by 156 · see citing works
Higham, C. E., Olsson-Brown, A., Carroll, P., Cooksley, T., Larkin, J., Lorigan, P., Morganstein, D., Trainer, P. J., & _, _. (2018) · Endocrine Connections · doi:10.1530/ec-18-0068 · Cited by 136 · see citing works
Diabetes and cancer (2): evaluating the impact of diabetes on mortality in patients with cancer
Renehan, A. G., Yeh, H., Johnson, J. A., Wild, S. H., Gale, E. A. M., & Møller, H. (2012) · Diabetologia · doi:10.1007/s00125-012-2526-0 · Cited by 132 · see citing works
Impact of Diabetes and Hyperglycemia on Survival in Advanced Breast Cancer Patients
Villarreal-Garza, C. M., Shaw-Dulin, R. J., Lara-Medina, F. U., Bacon, L., Rivera, D., Urzua, L., Águila, C., Ramírez-Morales, R., Santamaria, J., Bargalló, E., et al. (2012) · Experimental Diabetes Research · doi:10.1155/2012/732027 · Cited by 111 · see citing works
Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia
Chan, O., Talati, C., Isenalumhe, L. L., Shams, S. R., Nodzon, L., Fradley, M. G., Sweet, K. L., & Pinilla-Ibarz, J. A. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019000268 · Cited by 108 · see citing works
The impact of type 2 diabetes mellitus on cancer‐specific survival: A follow‐up study in sweden
Liu, X., Ji, J., Sundquist, K., Sundquist, J., & Hemminki, K. (2012) · Cancer · doi:10.1002/cncr.26420 · Cited by 97 · see citing works
Vergès, B. L., Walter, T., & Cariou, B. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0586 · Cited by 96 · see citing works
Ali, N. A., O’Brien, J. M., Blum, W. G., Byrd, J. C., Klisovic, R. B., Marcucci, G., Phillips, G. S., Marsh, C. B., Lemeshow, S. A., & Grever, M. R. (2007) · Cancer · doi:10.1002/cncr.22777 · Cited by 94 · see citing works
Belani, C. P., Brodowicz, T., Ciuleanu, T.-E., Kim, J. H., Krzakowski, M. J., Laack, E., Wu, Y.-L. L. C., Peterson, P. M., Krejcy, K., & Zielinski, C. C. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.cra8000 · Cited by 83 · see citing works
The expanding role of somatostatin analogs in the management of neuroendocrine tumors.
Wolin, E. M. (2012) · Europe PMC (PubMed Central) · Cited by 81 · see citing works
Panitumumab in Patients with KRAS Wild-Type Colorectal Cancer after Progression on Cetuximab
Wadlow, R. C., Hezel, A. F., Abrams, T. A., Blaszkowsky, L. S., Fuchs, C. S., Kulke, M. H., Kwak, E. L., Meyerhardt, J. A., Ryan, D. P., Szymonifka, J. D., et al. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0452 · Cited by 81 · see citing works
Feng, J. ‐., Yuan, X., Li, M., Fang, J., Xie, T., Zhou, Y., Zhu, Y., Luo, M.-H., Lin, M., & Ye, D. ‐. (2012) · Colorectal Disease · doi:10.1111/j.1463-1318.2012.03097.x · Cited by 79 · see citing works
Association between tamoxifen treatment and diabetes
Lipscombe, L. L., Fischer, H. D., Yun, L., Gruneir, A., Austin, P. C., Paszat, L. F., Anderson, G., & Rochon, P. A. (2011) · Cancer · doi:10.1002/cncr.26559 · Cited by 78 · see citing works
Ford, H. K. (1981) · BMJ · doi:10.1136/bmj.282.6268.994-c · Cited by 69 · see citing works
Sullivan, I., & Planchard, D. (2016) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465816670498 · Cited by 65 · see citing works
The association between diabetes/hyperglycemia and the prognosis of cervical cancer patients
Chen, S., Tao, M., Zhao, L., & Zhang, X. (2017) · Medicine · doi:10.1097/md.0000000000007981 · Cited by 56 · see citing works
Hyperglycemia is a significant prognostic factor of hepatocellular carcinoma after curative therapy
Hosokawa, T. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i2.249 · Cited by 54 · see citing works
Importance of glycemic control in cancer patients with diabetes: Treatment through end of life
Hershey, D. S. (2017) · Asia-Pacific Journal of Oncology Nursing · doi:10.4103/apjon.apjon_40_17 · Cited by 54 · see citing works
Androgen deprivation therapy is associated with diabetes: Evidence from meta‐analysis
Wang, H., Sun, X., Zhao, L., Chen, X., & Zhao, J. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12472 · Cited by 53 · see citing works
Hyperglycemia and prostate cancer recurrence in men treated for localized prostate cancer
Wright, J. L., Plymate, S. R., Porter, M. P., Gore, J. L., Lin, D. W., Hu, E., & Zeliadt, S. B. (2013) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2013.5 · Cited by 50 · see citing works
Impact of hyperglycemia on the efficacy of chemotherapy—A systematic review of preclinical studies
Gerards, M. C., Velden, D. L. V. D., Baars, J. W., Brandjes, D. P. M., Hoekstra, J. B. L., Vriesendorp, T. M., & Gerdes, V. E. A. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.03.007 · Cited by 49 · see citing works
Hyperglycaemia and Survival in Solid Tumours: A Systematic Review and Meta-analysis
Barua, R., Templeton, A. J., Šeruga, B., Ocaña, A., Amir, E., & Ethier, J.-L. (2018) · Clinical Oncology · doi:10.1016/j.clon.2018.01.003 · Cited by 49 · see citing works
Checkpoint inhibitor-induced insulin-dependent diabetes: an emerging syndrome
Perdigoto, A. L., Quandt, Z., Anderson, M. S., & Herold, K. C. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30072-5 · Cited by 48 · see citing works
Corticosteroid-Induced Diabetes in Palliative Care
Pilkey, J. L., Streeter, L., Beel, A., Hiebert, T., & Li, X. (2012) · Journal of Palliative Medicine · doi:10.1089/jpm.2011.0513 · Cited by 46 · see citing works
Glucocorticoid-induced diabetes mellitus in patients with lymphoma treated with CHOP chemotherapy
Lee, S., Kurita, N., Yokoyama, Y., Seki, M., Hasegawa, Y., Okoshi, Y., & Chiba, S. (2013) · Supportive Care in Cancer · doi:10.1007/s00520-013-2097-8 · Cited by 43 · see citing works
The Hospital Management of Hypoglycaemia in Adults with Diabetes Mellitus
September, R. (2013) · Cited by 41 · see citing works
Villadolid, J. J., Ersek, J. L., Fong, M. K., Sirianno, L., & Story, E. S. (2015) · PubMed Central · doi:10.3978/j.issn.2218-6751.2015.10.01 · Cited by 37 · see citing works
Novel cancer therapies and their association with diabetes
Shariff, A. I., Syed, S. H., Shelby, R. A., Force, J. M., Clarke, J. M., D’Alessio, D. A., & Corsino, L. (2018) · Journal of Molecular Endocrinology · doi:10.1530/jme-18-0002 · Cited by 36 · see citing works
Saglio, G. N., Larson, R. A., Hughes, T. P., Issaragrisil, S., Turkina, A., Marin, D., Zanichelli, M. A., Shibayama, H., Kalaycio, M. E., Huguet, F., et al. (2010) · Blood · doi:10.1182/blood.v116.21.3430.3430 · Cited by 34 · see citing works
Zylla, D. M., Gilmore, G., Eklund, J. P., Richter, S. A., & Carlson, A. L. (2019) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2018.12.012 · Cited by 34 · see citing works
Lü, J., Yang, J., Liang, Y., Meng, H., Zhao, J., & Zhang, X. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01453 · Cited by 34 · see citing works
Flanagan, D., Dhatariya, K., Kilvert, A., & the Joint British Diabetes Societies (JBDS) for Inpatient Care group and Guidelines writing group (2018) · Diabetic Medicine · doi:10.1111/dme.13677 · Cited by 33 · see citing works
Self-citationPalliative and end of life care of people with diabetes: issues, challenges and strategies
Dunning, T., & Martin, P. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.09.018 · Cited by 32 · see citing works
Barba, M., Sperati, F., Stranges, S., Carlomagno, C., Nasti, G., Iaffaioli, V. R., Caolo, G., Mottolese, M., Botti, G., Terrenato, I., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr540 · Cited by 29 · see citing works
Risk of hyperglycemia attributable to everolimus in cancer patients: A meta-analysis
Xu, K., Shameem, R., & Wu, S. (2016) · Acta Oncologica · doi:10.3109/0284186x.2016.1168939 · Cited by 27 · see citing works
Diabetes Mellitus Following Cisplatin Treatment
Nan, D., Fernández‐Ayala, M., Villegas, M. E. V., García‐Castaño, A., Rivera, F., López-Brea, M., & Gonzalez-Macyas, J. (2003) · Acta Oncologica · doi:10.1080/0891060310002276 · Cited by 26 · see citing works
Alpelisib for PIK3CA -Mutated Advanced Breast Cancer
André, F., Mills, D., & Taran, T. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1907856 · Cited by 26 · see citing works
Ali, N. A., O’Brien, J. M., Blum, W. G., Klisovic, R. B., Marcucci, G., Phillips, G. S., Marsh, C. B., Lemeshow, S. A., Byrd, J. C., & Grever, M. R. (2006) · Blood · doi:10.1182/blood.v108.11.5515.5515 · Cited by 25 · see citing works
Ma, Y., Zhao, M., Liu, Y., Zhao, D., Wang, L., Chen, X., & Li, L. (2019) · Hematology · doi:10.1080/16078454.2019.1632407 · Cited by 25 · see citing works
Agostino, N. M., Chinchilli, V. M., Koszyk-Szewczyk, A., Gingrich, R., Sivik, J. M., & Drabick, J. J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.4623 · Cited by 24 · see citing works
ctor, Eloy, Tamez-P, rez, Dania, Lizet, Quintanilla-Flores, Ren, R., Rodr, Ed, X., et al. (2015) · World Journal of Diabetes · Cited by 24 · see citing works
Variations of blood glucose in cancer patients during chemotherapy
Yang, J., Jia, B., Qiao, Y., Chen, W., & Qi, X. (2016) · Nigerian Journal of Clinical Practice · doi:10.4103/1119-3077.187323 · Cited by 22 · see citing works
Prognostic Significance of Hyperglycemia in Patients with Brain Tumors: a Meta-Analysis
Liu, H., Liu, Z., Jiang, B., Ding, X., Huo, L., Wan, X. H., Liu, J., & Xia, Z. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9115-4 · Cited by 18 · see citing works
Park, J. H., Kim, H., Lee, H., & Yun, E. K. (2015) · European Journal of Oncology Nursing · doi:10.1016/j.ejon.2015.03.006 · Cited by 16 · see citing works
Ji, G., Jin, L., Wang, R., Bai, Y., Yao, Z.-X., Lu, L., Huang, J.-B., Liu, S., Li, H., Wang, Z., et al. (2013) · Medical Oncology · doi:10.1007/s12032-013-0687-4 · Cited by 16 · see citing works
Dashora, U. K., & Taylor, R. (2004) · Diabetic Medicine · doi:10.1046/j.1464-5491.2003.01026_21_3.x-i1 · Cited by 15 · see citing works
Hyperglycemia crisis in head and neck cancer patients with platinum-based chemotherapy
Huang, C., Lin, Y., Liu, Y.-H., Lin, S., & Kang, B. (2018) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2018.05.008 · Cited by 13 · see citing works
Dose-sensitive steroid-induced hyperglycaemia
Gannon, C., & Dando, N. (2010) · Palliative Medicine · doi:10.1177/0269216310377816 · Cited by 12 · see citing works
Prevalence of diabetes in patients admitted to a cancer hospital
Morganstein, D. L., Tan, S., Gore, M. E., & Feher, M. (2012) · The British Journal of Diabetes · doi:10.1177/1474651412459091 · Cited by 11 · see citing works
Glycaemic adverse drug reactions from anti-neoplastics used in treating pancreatic cancer
He, J., Yang, J., Jia, B., & Yan, J. (2017) · Nigerian Journal of Clinical Practice · doi:10.4103/njcp.njcp_444_16 · Cited by 10 · see citing works
Impact of diabetes on cancer chemotherapy outcome: A retrospective analysis
Attili, V. S. S., Bapsy, P., Dadhich, H., Batra, U., Lokanatha, D., & Babu, K. G. (2007) · International Journal of Diabetes in Developing Countries · doi:10.4103/0973-3930.38631 · Cited by 9 · see citing works
Chang, L., An, Y., Yang, S., & Zhang, X. (2016) · Journal of Cancer Research and Therapeutics · doi:10.4103/0973-1482.191614 · Cited by 9 · see citing works
Risk Factors for Doxorubicin-Induced Serious Hyperglycaemia-Related Adverse Drug Reactions
Yang, J., Wang, Y., Liu, K., Yang, W. Y., & Zhang, J. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00677-0 · Cited by 9 · see citing works
Obesity and hyperglycemia as a bad prognosis factor for recurrence and survival in colon cancer
Calderillo-Ruiz, G., Lopez, H., Herrera, M., Trejo, E., Carbajal, B., Ramos-Ramírez, M., & Albarran, A. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz155.148 · Cited by 7 · see citing works
Kritharis, A., Bradley, T. P., & Budman, D. R. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.e19724 · Cited by 5 · see citing works
Rogers, E. S., Witton, E., STEWART, J. M., & Porter, D. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu356.62 · Cited by 2 · see citing works
Flagged first, then by citations
2 of the 76 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026
Bajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., ChallaSivaKanaka, S., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s009 · Cited by 302 · see citing works
Practical Guide to Glucocorticoid Induced Hyperglycaemia and Diabetes
Barker, H. L., Morrison, D., Llano, A., Sainsbury, C. A. R., & Jones, G. C. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01393-6 · Cited by 58 · see citing works
Percik, R., Criseno, S., Adam, S., Young, K., & Morganstein, D. L. (2023) · Endocrine Connections · doi:10.1530/ec-22-0513 · Cited by 28 · see citing works
Natalicchio, A., Marrano, N., Montagnani, M., Gallo, M., Faggiano, A., Zatelli, M., Argentiero, A., Re, M. D., D’Oronzo, S., Fogli, S., et al. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02417-z · Cited by 25 · see citing works
Hyperglycaemia following immune checkpoint inhibitor therapy—Incidence, aetiology and assessment
Mulla, K., Farag, S., Moore, B., Matharu, S. S., Young, K., Larkin, J., Popat, S., & Morganstein, D. L. (2023) · Diabetic Medicine · doi:10.1111/dme.15053 · Cited by 19 · see citing works
Rashid, R. S. M., Temurlu, S., Abourajab, A., Karsili, P., Dinleyici, M., Al-Khateeb, B., & Icil, H. (2023) · Pharmaceuticals · doi:10.3390/ph16040555 · Cited by 16 · see citing works
Ling, S., Sweeting, M. J., Zaccardi, F., Adlam, D., & Kadam, U. T. (2022) · BMC Cancer · doi:10.1186/s12885-022-10144-y · Cited by 14 · see citing works
Legris, P., Bouillet, B., Pâris, J., Pistre, P., Devaux, M., Bost, S., Simoneau, I., Manfrédi, S., Drouillard, A., Bastie, J.-N., et al. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02032-z · Cited by 10 · see citing works
Ashley, L., Kassim, S., Kellar, I., Kidd, L., Mair, F. S., Matthews, M., Price, M. L., Swinson, D., Taylor, J., Velikova, G., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-060402 · Cited by 11 · see citing works
Diabetes and cancer: Optimising glycaemic control
Joharatnam‐Hogan, N., & Morganstein, D. L. (2022) · Journal of Human Nutrition and Dietetics · doi:10.1111/jhn.13051 · Cited by 10 · see citing works
Self-citationAdvances in the treatment of glioma-related signaling pathways and mechanisms by metformin
Ma, X., Sun, C., Ding, X., Zhang, Y., Deng, T., Wang, Y., Yang, H., Ding, R., Li, H., Wang, D., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1482050 · Cited by 9 · see citing works
Santo, V., Brunetti, L., Pecci, F., Peroni, M., Barnini, G., Paoloni, F., Buti, S., Tiseo, M., Ricciuti, B., Pinato, D. J., et al. (2025) · Current Oncology Reports · doi:10.1007/s11912-025-01718-7 · Cited by 10 · see citing works
Wuthikraikun, C., Panja, P., Decha-Umphai, C., Sananpanichkul, N., Lawsereevanich, P., Kobkarnsakul, T., & Ngaosuwan, K. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2575108 · Cited by 6 · see citing works
Winn, M., Pauleck, S., Richardson, S., Viskochil, R. H., Karra, P., Colman, H., Doherty, J. A., Xu, Y., Hu‐Lieskovan, S., Litchman, M. L., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70311 · Cited by 6 · see citing works
Management of Glucocorticoid-Induced Hyperglycemia in Cancer Patients: A Feasibility Study
Wright, J., Nielsen, T., Burns, S., Weekes, N., Pradhan, A., Teus, J. K., & McErlean, G. (2024) · Clinical Nursing Research · doi:10.1177/10547738241291272 · Cited by 6 · see citing works
Morikawa, L. L., Nery, M., & Toyoshima, M. T. K. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.01.024 · Cited by 5 · see citing works
Salgado, T. M., Birari, P. B., Alshahawey, M., Hickey, E., Mackler, E. R., Buffington, T. M., Musselman, K. T., Irvin, W., Perkins, J. M., Le, T. N. H., et al. (2024) · Supportive Care in Cancer · doi:10.1007/s00520-024-08756-0 · Cited by 5 · see citing works
Cardiometabolic perturbations arising from treatment with novel anticancer therapies
Bennetts, J. D., Sverdlov, A. L., & Ngo, D. T. M. (2025) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2025.10.008 · Cited by 5 · see citing works
Development of insulin and its pharmacology and perioperative use: a narrative review
Dhatariya, K., Levy, N., Stubbs, D. J., Frank, C., Tinsley, S. L., & Knaggs, R. (2025) · British Journal of Anaesthesia · doi:10.1016/j.bja.2025.05.006 · Cited by 5 · see citing works
Self-citationThe critical need for guidance in managing glycaemic control in patients with cancer
Giovannucci, E. L. (2021) · Diabetic Medicine · doi:10.1111/dme.14624 · Cited by 5 · see citing works
Salgado, T. M., Radwan, R. M., Hickey, E., Mackler, E. R., Buffington, T. M., Musselman, K. T., Irvin, W., Perkins, J. M., Le, T. N. H., Dixon, D. L., et al. (2023) · Supportive Care in Cancer · doi:10.1007/s00520-023-07927-9 · Cited by 4 · see citing works
Katz, A., Shulkin, A., Housni, A., Roy‐Fleming, A., Rabasa‐Lhoret, R., Yale, J., Tsoukas, M. A., Peters, T. M., & Brazeau, A. (2026) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.70465 · Cited by 3 · see citing works
Ose, D. J., Adediran, E., Mark, B., Ocier, K., Dunson, W. A., Jr., Turner, C., Taylor, B., Svoboda, K., Post, A. R., Leiser, J. S., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.70246 · Cited by 3 · see citing works
Gallo, M., Lasagna, A., Renzelli, V., Morviducci, L., Cortellini, A., Monami, M., Marino, G., Gori, S., Verzè, M., Ragni, A., et al. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02586-5 · Cited by 3 · see citing works
Palliative management of type 2 diabetes mellitus in patients with advanced cancer
Weerasinghe, A., Good, P. D., Stokes, C., Chen, J., & Gurgenci, T. (2025) · Australian Journal of General Practice · doi:10.31128/ajgp-01-25-7522 · Cited by 3 · see citing works
Glycemic management in patients with immune-related diabetes mellitus: A scoping review
Jiang, Y., Wang, X., Lei, L., Liu, L., Wu, D., Zhang, S., Tang, D., Fan, L., Zhou, W., Xue, X., et al. (2025) · SAGE Open Medicine · doi:10.1177/20503121251358313 · Cited by 2 · see citing works
Zanfardino, A., Bruzzi, P., Trada, M., Rapini, N., Laudani, E., Tornese, G., Ortolani, F., Piccolo, G., Matonti, L., Saltarelli, M. A., et al. (2024) · Pediatric Hematology and Oncology · doi:10.1080/08880018.2023.2295454 · Cited by 2 · see citing works
Elevated glucose levels in melanoma patients − a real-world analysis
Walter, J. E., Bojanic, B., Dittli, M., Fehr, N., Sartoretti, T., Schwyzer, M., Binz, K., Gennari, A. G., Ernst, M., Huellner, M. W., et al. (2025) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2025.100405 · Cited by 2 · see citing works
Diabetes management during the end of life
Alsararatee, H. H., & Fusco, M. D. (2025) · British Journal of Nursing · doi:10.12968/bjon.2025.0339 · Cited by 1 · see citing works
Elevated fasting glucose is common in lung cancer patients undergoing 18F-FDG PET/CT: A brief report
Bojanic, B., Schwyzer, M., Sartoretti, T., Fischer, A., Binz, K., Hofer, G., Gennari, A. G., Ernst, M., Huellner, M. W., Walter, J. E., et al. (2025) · Metabolism Open · doi:10.1016/j.metop.2025.100406 · Cited by 1 · see citing works
Tislelizumab-induced fulminant type 1 diabetes mellitus (FT1D): A case report and literature review
Zhou, X., Peng, J. C., Chen, M., & Chen, J. (2025) · Medicine · doi:10.1097/md.0000000000046310 · Cited by 1 · see citing works
Diabetes Mellitus and Oncology: A Comprehensive Review
Kapoor, M., Kapoor, A., & Kant, R. (2026) · Indian Journal of Medical and Paediatric Oncology · doi:10.1055/s-0046-1820120 · Cited by 1 · see citing works
Bánhegyi, R. J., Veréb, B., Gazdag, A., Rácz, B., Wagner, R. J., Fülöp, N., & Pikó, B. (2022) · Orvosi Hetilap · doi:10.1556/650.2022.32635 · Cited by 1 · see citing works
Immune checkpoint inhibitor‐induced diabetes: Twists and turns of diabetology
Majić, A., & Berković, M. C. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15848
Tak, M. B., Munir, Z., & Aydın, A. (2024) · Cureus · doi:10.7759/cureus.73049
Evaluating oncology healthcare professionals’ knowledge of diabetes mellitus
Osgood, L., Gityamwi, N., & Cooke, D. D. (2024) · Cancer Nursing Practice · doi:10.7748/cnp.2024.e1880
Igbinosa, E. G., Dharmasekara, B., Quint, J. K., Popat, S., Bhaskaran, K., Morganstein, D. L., & Cook, S. (2025) · Clinical Epidemiology · doi:10.2147/clep.s498368
Zhou, C., Chen, H., Li, J., Hong, S., Sheng, X., & Zhou, A. (2025) · European Journal of Oncology Nursing · doi:10.1016/j.ejon.2025.102982
SASA Congress Refresher Course Abstracts 2025
(2025) · Southern African Journal of Anaesthesia and Analgesia · doi:10.36303/sajaa.3399
National Survey of the JBDS-IP/UK SACT board guidelines on the management of glycaemiaPreprint
Awoyemi, D., Chambers, P., Morganstein, D. L., Dhatariya, K., Ruth Board, Joharatnam‐Hogan, N., & Tomlins, E. (2026) · Research Square · doi:10.21203/rs.3.rs-8652042/v1
Self-citationBentley, R., Roberts, J. A., Saville, E., Alabdullatif, S., Perkins, D., Fogg, P., Keay, L. M., Gent, D. G., Jenkins, R. E., Rainbow, R. D., et al. (2026) · Pharmacological Research - Reports · doi:10.1016/j.prerep.2026.100086
Crockett, A., McCAUGHEY, C., Dornan, M., Donovan, M., & Aughey, E. (2026) · Supportive Care in Cancer · doi:10.1007/s00520-026-10947-w
Elevated Fasting Glucose in Patients with Lymphoma: A Real-World Observational Study
Fehr, N., Walter, J. E., Bojanic, B., Sartoretti, T., Schwyzer, M., Binz, K., Gennari, A. G., Huellner, M. W., Messerli, M., & Ernst, M. (2026) · Diabetology · doi:10.3390/diabetology7070126
Shaver, A. L., Steinbock-Malfer, C., Tester, W., Mille, P. J., Kelly, W. K., Zarrabi, K. K., Lallas, C. D., Shah, M. S., DiMarco, R., Brand, E., et al. (2026) · Cancer Medicine · doi:10.1002/cam4.72046
Garner, C., Miller, H., Slavova-Boneva, V., Kantilal, K., Kantilal, K., Mace, D., & Walsh, D. J. (2026) · Geriatric Pharmacology · doi:10.1080/2994399x.2026.2717013
Գլյուկոկորտիկոիդ-ասոցացված հիպերգլիկեմիայի կառավարումը օնկոլոգիական հիվանդների շրջանում
Մաղաքյան, Ս. Ա. (2026) · Medical Science of Armenia · doi:10.54503/0514-7484-2026-66.3-39
Lim, K. H., & Kim, J. (2026) · Nutrients · doi:10.3390/nu18193249
Type 2 diabetes medications and their implications for cancer treatment: A comprehensive review
Shakour, N., Hosseini, F., Esmaeili, Z., & Hadizadeh, F. (2026) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2026.101521
Vigus, S., Cranfield, A. A., Edmondston, S. J., & Feeney, K. (2026) · Research Square · doi:10.21203/rs.3.rs-10912205/v1
- Authors
- Joharatnam‐Hogan, N., Chambers, P., Dhatariya, K., Board, R., & the Joint British Diabetes Society for Inpatient Care (JBDS), U. C. B. (.
- Affiliations
- MRC Clinical Trials Unit at UCL (GB)
- University College London Hospitals NHS Foundation Trust (GB)
- Norfolk and Norwich University Hospital (GB)
- Lancashire Teaching Hospitals NHS Foundation Trust (GB)
- Corresponding author
- Joharatnam‐Hogan, Nalinie
- Venue
- Diabetic Medicine
- Publisher
- Wiley
- Published
- 2021-07-16
- Volume
- 39
- Issue
- 1
- Pages
- e14636-e14636
- ISSN
- 0742-3071 (ISSN-L)
- 1464-5491
- OpenAlex
- W3178817583
- Cited by
- 50
- References
- 76
- Citations by year
- 2026: 13 · 2025: 17 · 2024: 8 · 2023: 7 · 2022: 4 · 2021: 1
- FWCI
- 0.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetic Medicine (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- glycemic control, cancer, hyperglycemia, new-onset diabetes, diabetes mellitus, chemotherapy, glucocorticoids, outpatient management, multidisciplinary team, prognosis, overall survival, tumor recurrence
- MeSH terms
- Glycemic Control, Blood Glucose, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Neoplasms, Outpatients, Biomarkers, Practice Guidelines as Topic, Disease Management
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
